Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors

NCT01877811 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
143
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Hoffmann-La Roche